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BACKGROUND
Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoie-
sis-stimulating agent therapy is not effective generally become dependent on red-cell 
transfusions. Luspatercept, a recombinant fusion protein that binds transforming 
growth factor β superfamily ligands to reduce SMAD2 and SMAD3 signaling, showed 
promising results in a phase 2 study.
METHODS
In a double-blind, placebo-controlled, phase 3 trial, we randomly assigned patients 
with very-low-risk, low-risk, or intermediate-risk myelodysplastic syndromes (defined 
according to the Revised International Prognostic Scoring System) with ring sidero-
blasts who had been receiving regular red-cell transfusions to receive either luspater-
cept (at a dose of 1.0 up to 1.75 mg per kilogram of body weight) or placebo, admin-
istered subcutaneously every 3 weeks. The primary end point was transfusion 
independence for 8 weeks or longer during weeks 1 through 24, and the key secondary 
end point was transfusion independence for 12 weeks or longer, assessed during both 
weeks 1 through 24 and weeks 1 through 48.
RESULTS
Of the 229 patients enrolled, 153 were randomly assigned to receive luspatercept and 
76 to receive placebo; the baseline characteristics of the patients were balanced. Trans-
fusion independence for 8 weeks or longer was observed in 38% of the patients in the 
luspatercept group, as compared with 13% of those in the placebo group (P<0.001). A 
higher percentage of patients in the luspatercept group than in the placebo group met 
the key secondary end point (28% vs. 8% for weeks 1 through 24, and 33% vs. 12% for 
weeks 1 through 48; P<0.001 for both comparisons). The most common luspatercept-
associated adverse events (of any grade) included fatigue, diarrhea, asthenia, nausea, 
and dizziness. The incidence of adverse events decreased over time.
CONCLUSIONS
Luspatercept reduced the severity of anemia in patients with lower-risk myelodysplastic 
syndromes with ring sideroblasts who had been receiving regular red-cell transfusions 
and who had disease that was refractory to or unlikely to respond to erythropoiesis-
stimulating agents or who had discontinued such agents owing to an adverse event. 
(Funded by Celgene and Acceleron Pharma; MEDALIST ClinicalTrials.gov number, 
NCT02631070; EudraCT number, 2015 - 003454 - 41.)
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Luspatercept in Lower-Risk Myelodysplastic Syndromes
Myelodysplastic syndromes are ac-quired bone marrow disorders predom-inating in the elderly and are charac-
terized by ineffective hematopoiesis, progressive 
cytopenias, and risk of progression to acute 
myeloid leukemia.1 Lower-risk myelodysplastic 
syndromes most commonly manifest with symp-
tomatic anemia. (Lower-risk myelodysplastic syn-
dromes are defined according to the Interna-
tional Prognostic Scoring System [IPSS]2 as being 
of low or intermediate 1 risk or according to the 
Revised IPSS [IPSS-R] as being of very low, low, 
or intermediate risk; see the protocol and the 
Supplementary Methods section in the Supple-
mentary Appendix, both available with the full 
text of this article at NEJM.org.) In elderly per-
sons, chronic anemia is associated with multiple 
complications, including cardiovascular compli-
cations, increased risks of falls and bone frac-
ture, and shorter survival.3-5 A high proportion 
of patients with lower-risk myelodysplastic syn-
dromes eventually become dependent on red-cell 
transfusions, a situation that is associated with 
reduced quality of life and overall survival.5-12
Treatment goals for patients with lower-risk 
myelodysplastic syndromes include transfusion 
independence, improvement in hemoglobin levels, 
and maintenance of or improvement in quality of 
life.5,13,14 Erythropoiesis-stimulating agents are a 
first-line treatment for lower-risk myelodysplas-
tic syndromes,1,5 targeting early stages of eryth-
ropoiesis by inhibiting apoptosis and stimulating 
erythropoietin-responsive erythroid precursor pro-
liferation.15,16 Patients who are dependent on trans-
fusions5,17-21 or who have serum erythropoietin 
levels above 200 U per liter5,18,20-22 are less likely 
to have a response to erythropoiesis-stimulating 
agents than are patients who are not dependent 
on transfusions or who have serum erythropoietin 
levels below 200 U per liter; patients with myelo-
dysplastic syndromes with ring sideroblasts have 
a shorter median duration of response to erythro-
poiesis-stimulating agents than those who do not 
have ring sideroblasts.1,5,17,22,23 Although lenalido-
mide is an established treatment for patients with 
lower-risk myelodysplastic syndromes with chro-
mosome 5q deletion (del[5q]) who are dependent 
on transfusions, regardless of previous treatment 
with erythropoiesis-stimulating agents,5,24 only 
39% of other patients with lower-risk myelodys-
plastic syndromes receive second-line therapy aside 
from ongoing red-cell transfusions.22 Given the 
limited number of approved and effective treat-
ments, new treatment strategies are needed for 
patients with non-del(5q) lower-risk myelodys-
plastic syndromes who are dependent on trans-
fusions.1,5
Signaling by means of the SMAD2–SMAD3 
pathway is constitutively increased in the bone 
marrow cells of patients with myelodysplastic 
syndromes and in disease models with ineffec-
tive erythropoiesis, including β-thalassemia.25-27 
SMAD2 and SMAD3 signaling exerts an inhibitory 
effect on red-cell maturation. Luspatercept is a re-
combinant fusion protein that binds select trans-
forming growth factor β superfamily ligands to 
decrease SMAD2 and SMAD3 signaling, thereby 
enabling erythroid maturation by means of late-
stage erythroblast differentiation.28,29 In mouse 
models of myelodysplastic syndromes and β-thalas-
semia, luspatercept decreased SMAD2 and SMAD3 
signaling, reduced erythroid hyperplasia, enhanced 
erythroid maturation, and increased hemoglobin 
levels.27,28 Luspatercept consists of a modified ex-
tracellular domain of the human activin receptor 
type IIB linked to the human IgG1 Fc domain,28 
which eliminates activin A binding to minimize 
nonhematologic effects.
In a phase 2 study involving patients with 
lower-risk myelodysplastic syndromes, 63% of 
luspatercept-treated patients had an erythroid re-
sponse (also called hematologic improvement–
erythroid; defined according to the International 
Working Group [IWG] 2006 criteria14 as a reduction 
in red-cell transfusions of ≥4 units per 8 weeks 
in patients with a baseline transfusion burden of 
≥4 units per 8 weeks or as an increase in the 
hemoglobin level of ≥1.5 g per deciliter over a 
period of 8 weeks in patients with a baseline 
transfusion burden of <4 units per 8 weeks) and 
38% had transfusion independence for 8 weeks 
or longer.30 The overall erythroid response rate 
was higher among patients with ring sideroblasts 
(≥15% ring sideroblasts) than among patients 
with other subtypes of lower-risk myelodysplas-
tic syndromes. MEDALIST was a phase 3 trial 
evaluating the safety and efficacy of luspatercept 
in patients with IPSS-R–defined lower-risk my-
elodysplastic syndromes with ring sideroblasts 
who had been receiving regular red-cell transfu-
sions and had disease that was refractory to or 
unlikely to respond to erythropoiesis-stimulat-
ing agents or who had discontinued such agents 
owing to an adverse event.
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Me thods
Trial Design and Oversight
We conducted this randomized, double-blind, 
placebo-controlled trial at 65 sites in 11 countries 
(see the Supplementary Appendix). Investigators 
conducted the trial according to institutional and 
CONSORT (Consolidated Standards of Reporting 
Trials) guidelines and in accordance with the laws 
of applicable authorities. Institutional review 
boards or ethics committees at each site approved 
the protocol. All the patients provided written 
informed consent. The primary sponsor (Celgene), 
the authors, and the investigators designed the 
trial in collaboration with the external steering 
committee; an independent data and safety mon-
itoring board monitored the trial. Acceleron Phar-
ma collaborates with Celgene in the development 
of luspatercept for the treatment of chronic 
anemia in patients with myelodysplastic syn-
dromes. Acceleron Pharma provided guidance 
in the development of the trial design and as-
sessment of data collection. Authors who are 
employees of Acceleron Pharma provided criti-
cal review and modifications to the manuscript, 
as well as approving the final version of the 
manuscript.
The authors vouch for the accuracy and com-
pleteness of the data and for the adherence of 
the trial to the protocol. Editorial and writing 
assistance was provided by a medical writer, 
funded by Celgene.
Patients
Eligible patients were 18 years of age or older 
and had a myelodysplastic syndrome with ring 
sideroblasts according to World Health Organi-
zation criteria (i.e., with either ≥15% ring sidero-
blasts or ≥5% ring sideroblasts if an SF3B1 muta-
tion was present, and with <5% bone marrow 
blasts)31,32; had disease that was defined accord-
ing to the IPSS-R as being of very low, low, or 
intermediate risk; had been receiving regular red-
cell transfusions (≥2 units per 8 weeks during 
the 16 weeks before randomization); and had dis-
ease that was refractory to or was unlikely to re-
spond to erythropoiesis-stimulating agents (owing 
to an endogenous erythropoietin level of >200 U 
per liter in those who had not previously been 
treated with erythropoiesis-stimulating agents) 
or had discontinued such agents owing to an 
adverse event. Additional eligibility and exclu-
sion criteria are listed in the Supplementary Ap-
pendix.
Trial Design
In the double-blind primary phase of the trial, 
patients were randomly assigned in a 2:1 ratio to 
receive luspatercept or placebo, administered sub-
cutaneously every 3 weeks for 24 weeks; no cross-
over was allowed. The starting dose of luspater-
cept was 1.0 mg per kilogram of body weight. If a 
new transfusion was deemed to be necessary after 
the patient was considered to have transfusion 
independence, patients could continue receiving 
luspatercept, with adjustment to a dose of 1.33 mg 
per kilogram and then to 1.75 mg per kilogram 
(Table S1 in the Supplementary Appendix).
Disease assessment occurred at week 25. Pa-
tients without clinical benefit (as assessed by the 
investigators) discontinued receiving luspatercept 
or placebo and entered follow-up. Patients who 
had clinical benefit without disease progression 
(according to IWG 2006 criteria14) could enter the 
extension phase and continue receiving luspater-
cept or placebo (in a double-blind fashion) until 
they had unacceptable toxic effects or disease pro-
gression, withdrew consent, or met discontinua-
tion criteria. (The trial design is shown in Fig. S1.)
End-Point Measures
The primary end point was transfusion inde-
pendence for 8 weeks or longer during weeks 
1 through 24; this period of time (1 through 24 
weeks) was chosen to reduce potential bias due 
to loss of patients receiving placebo without an 
early response. The key secondary end point was 
transfusion independence for 12 weeks or longer, 
assessed during both weeks 1 through 48 and 
weeks 1 through 24. Other secondary end points 
included erythroid response (also called hemato-
logic response–erythroid; defined by the IWG 
2006 criteria14), longest duration of primary re-
sponse, mean increase in hemoglobin levels of at 
least 1.0 g per deciliter, progression to acute 
myeloid leukemia, mean change in the serum 
ferritin level, and safety analyses. Subgroup analy-
ses were performed as exploratory end points. 
Transfusion independence for 16 weeks or longer 
(during weeks 1 through 24 and weeks 1 through 
48) was also evaluated. Safety laboratory analy-
ses and assessments were performed centrally, 
whenever possible. All the primary and second-
ary end points are listed in Table S2.
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Statistical Analysis
The data-cutoff date was May 8, 2018. All the ef-
ficacy analyses were conducted in the intention-
to-treat population. Patients who did not have 
transfusion independence for 8 weeks or longer 
by week 24 were considered not to have had a 
response with regard to the primary end point. 
The percentages of patients with a response re-
garding the primary and key secondary end 
points were compared with the use of a Cochran–
Mantel–Haenszel test at a two-sided significance 
level of 0.05 and with randomization factors as 
strata: average baseline transfusion burden (≥6 
units per 8 weeks vs. <6 units per 8 weeks) and 
baseline IPSS-R category (very low or low risk vs. 
intermediate risk). A sequential gatekeeping ap-
proach was used for the primary and key second-
ary end points, which were tested sequentially in 
the prespecified order (stated above). The dura-
tion of transfusion independence of 8 weeks or 
longer was estimated with the use of Kaplan–
Meier analysis of the longest period of response 
at any dose. Safety analyses were conducted in 
the safety population (all the patients who re-
ceived ≥1 dose of luspatercept or placebo). (Ad-
ditional statistical methods are presented in the 
Supplementary Methods section in the Supple-
mentary Appendix.)
R esult s
Baseline Characteristics of the Patients
Overall, 229 patients were enrolled (from March 
2016 through June 2017); 153 patients were ran-
domly assigned to receive luspatercept, and 76 to 
receive placebo. The baseline characteristics of the 
patients were well balanced between the groups 
(Table 1 and Table S3). The median age of the 
patients was 71 years (range, 26 to 95), and 63% 
of the patients were men. With regard to the 
IPSS-R categories, 10%, 72%, and 17% of the 
patients had a myelodysplastic syndrome defined 
as being of very low risk, low risk, and interme-
diate risk, respectively.
The baseline serum erythropoietin levels were 
less than 100 U per liter, 100 to less than 200 U 
per liter, 200 to 500 U per liter, and more than 
500 U per liter in 36%, 24%, 25%, and 14% of 
the patients, respectively. The baseline transfu-
sion burden was at least 6 units per 8 weeks in 
43% of the patients and less than 6 units per 
8 weeks in 57%; 29% had a baseline burden of 
less than 4 units per 8 weeks. SF3B1 mutations 
were detected in 93% of the patients in the luspa-
tercept group (138 of 148 patients) and in 86% of 
those in the placebo group (64 of 74) (assessed on 
the basis of mutation profiles from bone mar-
row mononuclear cells obtained at baseline). 
Somatic mutations were distributed similarly in 
the two groups (Fig. S2 and Table S4).
Overall, the median transfusion burden over 
an 8-week period during the 16 weeks before 
treatment was 5 units per 8 weeks (range, 1 to 20). 
A total of 95% of the patients had received erythro-
poiesis-stimulating agents previously, and 48% 
had received iron chelation therapy previously.
Primary End Point
During the first 24 weeks of the trial, 58 patients 
(38%) in the luspatercept group had transfusion 
independence for 8 weeks or longer, as compared 
with 10 (13%) in the placebo group (P<0.001) 
(Fig. 1). With regard to the primary end point, 
the majority (62% [36 of 58]) of patients in the 
luspatercept group who had a response had at 
least two response intervals of transfusion inde-
pendence lasting 8 weeks or longer during treat-
ment, whereas all the patients with a response in 
the placebo group had two or fewer response 
intervals (Table S5). Although most patients in 
the luspatercept group who had a response (90% 
[52 of 58]) had their first response at the start-
ing dose (1.0 mg per kilogram), 7% had their 
first response after dose increases (2 patients 
each at the doses of 1.33 mg per kilogram and 
1.75 mg per kilogram). Among these 58 pa-
tients, 15 (26%) had an initial response at the 
1.0 mg per kilogram dose and 14 (24%) had 
subsequent response intervals at the same or 
higher doses (Table S6).
When evaluated according to the baseline 
transfusion burden, transfusion independence for 
8 weeks or longer in the luspatercept group oc-
curred in 80% of the patients (37 of 46) who had 
been receiving less than 4 units per 8 weeks, in 
37% of those (15 of 41) who had been receiving 
4 to less than 6 units per 8 weeks, and in 9% of 
those (6 of 66) who had been receiving at least 
6 units per 8 weeks; the corresponding values in 
the placebo group were 40% (8 of 20 patients), 
4% (1 of 23), and 3% (1 of 33). Among patients 
with a baseline serum erythropoietin level of 
200 to 500 U per liter, 40% of patients in the 
luspatercept group had a response (Fig. S3).
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The percentages of patients with a response 
were similar regardless of SF3B1 allelic bur-
den (data not shown) and the total number 
of baseline somatic mutations. In the luspa-
tercept group, transfusion independence for 
8 weeks or longer was observed in 36%, 35%, 
42%, and 33% of patients who had one base-
line mutation, two mutations, three muta-









Median age (range) — yr 71 (40–95) 72 (26–91) 71 (26–95)
Male sex — no. (%) 94 (61) 50 (66) 144 (63)
Median time since original diagnosis of MDS (range) — mo 44.0 (3–421) 36.1 (4–193) 41.8 (3–421)
WHO classification of MDS — no. (%)† 
MDS with refractory anemia with ring sideroblasts 7 (5) 2 (3) 9 (4)
MDS with refractory cytopenia with multilineage dysplasia‡ 145 (95) 74 (97) 219 (96)
IPSS-R risk category — no. (%)§
Very low 18 (12) 6 (8) 24 (10)
Low 109 (71) 57 (75) 166 (72)
Intermediate 25 (16) 13 (17) 38 (17)
Median serum erythropoietin level (range) — U/liter¶ 156.9 (12–2454) 130.8 (29–2760) 153.2 (12–2760)
Serum erythropoietin level category — no. (%)
<100 U/liter 51 (33) 31 (41) 82 (36)
100 to <200 U/liter 37 (24) 19 (25) 56 (24)
200 to 500 U/liter 43 (28) 15 (20) 58 (25)
>500 U/liter 21 (14) 11 (14) 32 (14)
Missing data 1 (1) 0 1 (<1)
Mutated SF3B1 — no./total no. (%)‖ 138/148 (93) 64/74 (86) 202/222 (91)
Median red-cell transfusion burden (range) — no. of units/8 wk 
over period of 16 wk**
5 (1–15) 5 (2–20) 5 (1–20)
Red-cell transfusion-burden category — no. (%)
≥6 units/8 wk 66 (43) 33 (43) 99 (43)
4 to <6 units/8 wk 41 (27) 23 (30) 64 (28)
<4 units/8 wk 46 (30) 20 (26) 66 (29)
Median pretransfusion hemoglobin level (range) — g/dl†† 7.6 (6–10) 7.6 (5–9) 7.6 (5–10)
Received ESA previously — no. (%) 148 (97) 70 (92) 218 (95)
Disease refractory to ESA — no./total no. (%) 144/148 (97) 69/70 (99) 213/218 (98)
Discontinued previous ESA-containing regimen owing to an ad-
verse event — no./total no. (%)
4/148 (3) 1/70 (1) 5/218 (2)
Previous iron chelation therapy — no. (%) 71 (46) 40 (53) 111 (48)
Median platelet count (range) — 10−9/liter 235.0 (59–892) 222.5 (60–689) 234.0 (59–892)
*  Percentages may not total 100 because of rounding. ESA denotes erythropoiesis-stimulating agent, IPSS-R Revised International Prognostic 
Scoring System, MDS myelodysplastic syndrome, and WHO World Health Organization.
†  One patient in the luspatercept group had locally diagnosed MDS with ring sideroblasts with multilineage dysplasia.
‡  All the patients were classified as having refractory cytopenia with multilineage dysplasia with ring sideroblasts because they were required 
to have ring sideroblasts according to the inclusion criteria.
§  MDS in one patient (1%) in the luspatercept group was classified as IPSS-R high-risk. This case was a protocol violation, and the patient 
entered the trial in error.
¶  The baseline erythropoietin level was defined as the highest erythropoietin value within 35 days before the first dose.
‖  The analysis included only patients with available baseline gene mutation data.
**  The analysis included data only within the 16 weeks before randomization.
††  The pretransfusion hemoglobin level was defined as the last value measured on or before the date and time of the first dose.
Table 1. Demographic and Disease Characteristics of the Patients at Baseline.*
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 Key Secondary End Point and Additional 
Secondary End Points
During the first 24 weeks, 43 patients (28%) in 
the luspatercept group had transfusion indepen-
dence for 12 weeks or longer, as compared with 
6 (8%) in the placebo group, and the correspond-
ing values during weeks 1 through 48 were 51 
patients (33%) and 9 (12%) (P<0.001 for both 
comparisons) (Fig. 1). In addition, in the analy-
sis that applied the new IWG 2018 response cri-
teria,33 a greater percentage of patients in the 
luspatercept group than in the placebo group had 
transfusion independence for 16 weeks or longer 
(19% vs. 4% during weeks 1 through 24, and 
28% vs. 7% during weeks 1 through 48) (Fig. 1).
At the data cutoff, the median duration of the 
longest single period of transfusion independence 
(in patients who met the primary end point) was 
30.6 weeks in the luspatercept group and 13.6 
weeks in the placebo group (Table S7); 22 pa-
tients (14%) in the luspatercept group had the 
response (independence from red-cell transfu-
sions for ≥8 weeks, with the criterion met during 
weeks 1 through 24) maintained at 1 year (data 
not shown). Overall, at the data cutoff, 46% of 
the patients were continuing to receive luspater-
cept and 8% were continuing to receive placebo 
(Table S8). Treatment exposure is discussed 
further in the Supplementary Appendix.
During weeks 1 through 24, an erythroid re-
sponse occurred in 81 patients (53%) in the lus-
patercept group, as compared with 9 (12%) in the 
placebo group. During weeks 1 through 48, a total 
of 90 patients (59%) in the luspatercept group had 
an erythroid response, as compared with 13 
(17%) in the placebo group (Table 2). No signifi-
cant changes in neutrophil or platelet counts 
were observed during the double-blind period.
During weeks 1 through 24, a mean increase 
in the hemoglobin level of at least 1.0 g per deci-
liter occurred in 54 patients (35%) in the luspater-
cept group and in 6 (8%) in the placebo group; 
during weeks 1 through 48, the increases oc-
curred in 63 patients (41%) and 8 patients (11%), 
respectively (Table 2). Over time, patients in the 
luspatercept group had greater mean hemoglobin 
levels than those in the placebo group (Fig. 2A). 
In the luspatercept group, increases in the hemo-
Figure 1. Independence from Red-Cell Transfusion.
Shown are the percentages of patients who had independence from red-cell transfusion (defined as the absence of 
a red-cell transfusion) for the indicated time periods in each trial group. In the analysis of the primary end point 
(transfusion independence for ≥8 weeks during weeks 1 through 24), the odds ratio for luspatercept as compared 
with placebo was 5.07 (95% confidence interval [CI], 2.28 to 11.26). For the key secondary end point of transfusion 
independence for 12 weeks or longer, the odds ratio was 5.07 (95% CI, 2.00 to 12.84) for the analysis period of weeks 
1 through 24 and 4.05 (95% CI, 1.83 to 8.96) for the analysis period of weeks 1 through 48. P values were determined 
with the use of a Cochran–Mantel–Haenszel test with stratification for average baseline red-cell transfusion burden 
(≥6 units per 8 weeks vs. <6 units per 8 weeks) and baseline Revised International Prognostic Scoring System score 
(very low or low risk vs. intermediate risk). An analysis that applied the new International Working Group 2018 response 
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10 (13 [6–23])  
43 (28 [21–36])




3 (4 [1–11])  
43 (28 [21–36])
5 (7 [2–15])  
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globin level were greater over time among pa-
tients who had a response regarding transfusion 
independence than among those who did not 
have a response (Fig. 2B), regardless of baseline 
transfusion burden. Among patients in the lus-
patercept group who had a response, the median 
peak increase in the hemoglobin level was 2.55 g 
per deciliter (range, 1.0 to 4.1).
Patients in the luspatercept group had greater 
reductions from baseline than those in the pla-
cebo group in the mean serum ferritin level, 
averaged over weeks 9 through 24. The least-
squares mean difference (luspatercept vs. placebo) 
was −229.1 μg per liter (Table S9).
Safety
The most frequently reported adverse events dur-
ing the trial (of any grade and occurring in 
≥10% of patients) with luspatercept or placebo 
were as follows: fatigue (in 27% and 13%, respec-
tively), diarrhea (in 22% and 9%), asthenia (in 
20% and 12%), nausea (in 20% and 8%), dizzi-
ness (in 20% and 5%), and back pain (in 19% and 
7%) (Table 3). Overall, 65 patients (42%) receiv-
ing luspatercept and 34 (45%) receiving placebo 
had adverse events of grade 3 or 4 during the 
trial (Table S10; specific grade 3 or 4 adverse 
events are listed in Table S11). A total of 48 pa-
tients (31%) receiving luspatercept had at least 
one serious adverse event, as compared with 23 
(30%) receiving placebo.
Seven patients (5%) receiving luspatercept and 
none of the patients in the placebo group had a 
dose reduction due to adverse events (Table S12). 
Overall, 13 patients (8%) receiving luspatercept 
and 6 (8%) receiving placebo discontinued the 
trial regimen because of adverse events. Adverse 
events leading to the discontinuation of luspa-
tercept therapy included fatigue (in 1% of pa-
tients) and headache (in 1%) (data not shown). 
Adverse events occurring more frequently during 
cycles 1 through 4 of luspatercept treatment in-
cluded fatigue, diarrhea, asthenia, and dizziness; 
the incidence declined thereafter and was not 
associated with dose adjustment (Table S13 and 
data not shown). Three patients receiving luspa-
tercept had dose reductions per protocol owing 
to increases in the hemoglobin level of 2.0 g per 
deciliter or more (Table S14).
One patient in each group had progression to 
higher-risk myelodysplastic syndromes, and acute 






Erythroid response during wk 1–24*
No. of patients (% [95% CI]) 81 (53 [45–61]) 9 (12 [6–21])
Reduction of ≥4 red-cell units/8 wk — no./total no. (%)† 52/107 (49) 8/56 (14)
Mean increase in hemoglobin level of ≥1.5 g/dl — no./total no. (%)‡ 29/46 (63) 1/20 (5)
Erythroid response during wk 1–48*
No. of patients (% [95% CI]) 90 (59 [51–67]) 13 (17 [9–27])
Reduction of ≥4 red-cell units/8 wk — no./total no. (%)† 58/107 (54) 12/56 (21)
Mean increase in hemoglobin level of ≥1.5 g/dl — no./total no. (%)‡ 32/46 (70) 1/20 (5)
Mean increase in hemoglobin level of ≥1.0 g/dl — no. (% [95% CI])§
During wk 1–24 54 (35 [28–43]) 6 (8 [3–16])
During wk 1–48 63 (41 [33–49]) 8 (11 [5–20])
*  Analysis was based on the proportion of patients meeting the modified criteria for erythroid response (also called he-
matologic improvement–erythroid) according to International Working Group 2006 criteria14 sustained over a consecu-
tive 56-day period during the indicated treatment period: for patients with baseline red-cell transfusion burden of at least  
4 units per 8 weeks, a transfusion reduction of at least 4 red-cell units per 8 weeks; and for patients with baseline red-
cell transfusion burden of less than 4 units per 8 weeks, a mean increase of hemoglobin of at least 1.5 g per deciliter.
†  Analysis was based on the number of patients with baseline red-cell transfusion burden of at least 4 units per 8 weeks.
‡  Analysis was based on the number of patients with baseline red-cell transfusion burden of less than 4 units per 8 weeks.
§  Analysis was based on the proportion of patients with an increase from baseline of at least 1 g per deciliter (>14 days 
after the last red-cell transfusion or within 3 days before the next red-cell transfusion) that was sustained over any con-
secutive 56-day period in the absence of red-cell transfusions.
Table 2. Erythroid Response and Increase in Mean Hemoglobin Levels.
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Figure 2. Changes in Mean Hemoglobin Levels over Time.
Panel A shows the mean observed hemoglobin values over time (baseline through week 25) for each trial group. The 
baseline value was defined as the lowest of the pretreatment or baseline values from the central or local laboratory or 
the lowest pretransfusion hemoglobin value from transfusion records that were within 35 days before the first dose of 
luspatercept or placebo. Panel B shows the mean change in hemoglobin level over time in patients in the luspatercept 
group who had a response with regard to the primary end point and in those in the luspatercept group who did not 
have a response, as compared with patients who received placebo (baseline through week 25). (At baseline, there were 
153 patients in the overall luspatercept group and 76 in the placebo group.) The least-squares mean difference among 
patients in the luspatercept group who had a response, as compared with patients in the placebo group, was 1.08 
(95% CI, 0.84 to 1.31). The median peak improvement in hemoglobin level in patients in the luspatercept group who 
had a response was 2.55 g per deciliter (range, 1.0 to 4.1). The mean values and standard errors were not calculated if 
the number of patients was less than 8 in the luspatercept group of patients without a response or if the number was 
less than 4 in the placebo group. Hemoglobin values that were obtained within 14 days after a red-cell transfusion 
were censored from these analyses unless they also were within 3 days before receipt of another red-cell transfusion. 
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tients [2%] receiving luspatercept and 1 [1%] re-
ceiving placebo). A total of 21 patients died dur-
ing the trial: 12 patients (8%) in the luspatercept 
group and 9 (12%) in the placebo group (data 
not shown). Overall, 5 patients (3%) receiving 
luspatercept and 4 (5%) receiving placebo died 
owing to adverse events during the double-blind 
period or within 6 weeks thereafter; investigators 
judged the deaths to be unrelated to luspatercept 
or placebo.
Discussion
In this phase 3 trial involving patients with 
lower-risk myelodysplastic syndromes with ring 
sideroblasts who had been receiving regular red-
cell transfusions and had disease that was refrac-
tory to or unlikely to respond to erythropoiesis-
stimulating agents or who had discontinued such 
agents owing to an adverse event, 38% of the 
patients in the luspatercept group met the pri-
mary end point of transfusion independence for 
8 weeks or longer, as compared with 13% of those 
in the placebo group (P<0.001). The median du-
ration of the longest single continuous period of 
response to luspatercept was 30.6 weeks. Among 
patients who had a baseline transfusion burden 
of 4 to less than 6 units per 8 weeks, 37% of 
those in the luspatercept group and 4% of those 
in the placebo group had a response. This find-
ing was consistent with the results of the phase 2 
study, which included patients without ring sidero-
blasts and in which 38% of the patients in the 
luspatercept group had a response.30 Although the 
precise mechanism of action of luspatercept on 
SMAD2 and SMAD3 signaling remains incom-
pletely understood,34,35 the rapid onset of treat-
ment effect, extended duration of transfusion 
Event Luspatercept (N = 153) Placebo (N = 76)
Any Grade Grade 3 Any Grade Grade 3
number of patients with event (percent)
General disorder or administration-site condition
Fatigue 41 (27) 7 (5) 10 (13) 2 (3)
Asthenia 31 (20) 4 (3) 9 (12) 0
Peripheral edema 25 (16) 0 13 (17) 1 (1)
Gastrointestinal disorder
Diarrhea 34 (22) 0 7 (9) 0
Nausea† 31 (20) 1 (1) 6 (8) 0
Constipation 17 (11) 0 7 (9) 0
Nervous system disorder
Dizziness 30 (20) 0 4 (5) 0
Headache 24 (16) 1 (1) 5 (7) 0
Musculoskeletal or connective-tissue disorder
Back pain† 29 (19) 3 (2) 5 (7) 0
Arthralgia 8 (5) 1 (1) 9 (12) 2 (3)
Respiratory, thoracic, or mediastinal disorder
Dyspnea† 23 (15) 1 (1) 5 (7) 0
Cough 27 (18) 0 10 (13) 0
Infection or infestation
Bronchitis† 17 (11) 1 (1) 1 (1) 0
Urinary tract infection† 17 (11) 2 (1) 4 (5) 3 (4)
Injury, poisoning, or procedural complication: fall 15 (10) 7 (5) 9 (12) 2 (3)
*  Adverse events during the trial were not adjusted for treatment exposure.
†  At least one serious adverse event occurred: nausea (in one patient receiving luspatercept), back pain (in three receiv-
ing luspatercept), dyspnea (in one receiving luspatercept), bronchitis (in one receiving luspatercept), and urinary tract 
infection (in one receiving placebo).
Table 3. Adverse Events Occurring in at Least 10% of Patients.*
The New England Journal of Medicine 
Downloaded from nejm.org at UT AUSTIN on January 8, 2020. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med 382;2 nejm.org January 9, 2020 149
Luspatercept in Lower-Risk Myelodysplastic Syndromes
independence, erythroid response, and increased 
hemoglobin levels suggest that luspatercept had 
useful clinical effects in these patients.
Luspatercept was associated with mainly low-
grade toxic effects that seldom led to the discon-
tinuation of treatment. The incidence of adverse 
effects generally decreased over time among 
luspatercept-treated patients. Although the trial 
was underpowered for the systematic analysis of 
progression to acute myeloid leukemia, the inci-
dence was low in both groups and consistent 
with the natural history of lower-risk myelodys-
plastic syndromes with ring sideroblasts; long-
term follow-up is ongoing, and data from the 
phase 2 study showed no increased risk of pro-
gression to acute myeloid leukemia.30
The MEDALIST trial focused on patients with 
lower-risk myelodysplastic syndromes with ring 
sideroblasts because this is the largest subgroup 
of patients with myelodysplastic syndromes who 
have a low risk of progression to acute myeloid 
leukemia as well as prolonged survival, and 
therefore the treatment of anemia is particularly 
important in these patients. The COMMANDS 
trial (ClinicalTrials.gov number, NCT03682536) is 
evaluating the efficacy of luspatercept in other sub-
groups of patients with myelodysplastic syndromes.
Although there were potential differences in 
the criteria for response assessment between our 
trial and previous studies,36-38 luspatercept re-
sulted in a higher percentage of patients with a 
response or a better safety profile (or both) than 
were seen with previously evaluated treatments 
in patients with disease that was refractory or 
resistant to erythropoiesis-stimulating agents who 
had non-del(5q) transfusion-dependent lower-risk 
myelodysplastic syndromes. In a randomized, 
placebo-controlled trial of lenalidomide in such 
patients, transfusion independence for 8 weeks 
or longer was observed in 26.9% of lenalidomide-
treated patients (vs. 2.5% of those receiving 
placebo); among patients with ring sideroblasts 
(70.3% of all patients), 30.6% of patients in the 
lenalidomide group had a response.36 When our 
analysis was restricted to patients who had a 
response with regard to the primary end point 
and who had a similar red-cell transfusion burden 
as in the lenalidomide trial (≥4 units per 8 weeks), 
the percentage of patients with a response to 
luspatercept was similar to that with lenalido-
mide.36 However, in contrast to the current trial, 
grade 3 or 4 neutropenia and thrombocytopenia 
were reported in 61.9% and 35.6% of the lenalido-
mide-treated patients, respectively.36 In a random-
ized, phase 3 trial comparing lenalidomide with 
lenalidomide plus epoetin beta in patients with 
myelodysplastic syndromes that were resistant to 
erythropoiesis-stimulating agents and were de-
fined as being of low or intermediate 1 risk (ac-
cording to IPSS) with transfusion dependence, 
61.8% of the patients had ring sideroblasts.37 
Overall, 13.8% of the patients in the lenalido-
mide group and 24.2% of those in the group that 
received lenalidomide plus epoetin beta had trans-
fusion independence for 8 weeks or longer.37 
Moreover, in a phase 2 study evaluating azaciti-
dine with or without erythropoietin in patients 
with erythropoiesis-stimulating agent–resistant, 
transfusion-dependent, lower-risk myelodysplastic 
syndromes, transfusion independence for 8 weeks 
or longer was observed in 14.3% of patients re-
ceiving azacitidine plus erythropoietin and in 
16.3% of those receiving azacitidine; myelosup-
pression was also observed, a finding similar to 
other trials of azacitidine.38,39
Patients with lower-risk myelodysplastic syn-
dromes with ring sideroblasts for whom erythro-
poiesis-stimulating agents are not effective or are 
not an option have limited treatment options avail-
able beyond continued transfusions. Luspatercept 
significantly reduced the transfusion burden in a 
substantial proportion of these patients and was 
associated with mainly low-grade toxic effects.
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